These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23428390)

  • 1. Vaccination against meningococcus C. vaccinal coverage in the French target population.
    Stahl JP; Cohen R; Denis F; Gaudelus J; Lery T; Lepetit H; Martinot A
    Med Mal Infect; 2013 Feb; 43(2):75-80. PubMed ID: 23428390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of hepatitis B vaccine coverage rates in France between 2008 and 2011.
    Denis F; Cohen R; Martinot A; Stahl JP; Lery T; Le Danvic M; Gaudelus J
    Med Mal Infect; 2013 Jul; 43(7):272-8. PubMed ID: 23876204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of invasive diseases: strategies to increase vaccination coverage in children and adolescents.
    Zoppi G; Trucchi C
    J Prev Med Hyg; 2012 Jun; 53(2):125-9. PubMed ID: 23240175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal C vaccine coverage in France in infants, children, and adolescents.
    Gaudelus J; Cohen R; Leboucher B; Stahl JP; Denis F; Pujol P; Longfier L; Martinot A
    Med Mal Infect; 2019 May; 49(3):180-186. PubMed ID: 30826174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
    Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
    J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccination of teenagers. Mission: impossible?].
    Gaudelus J; Cohen R; Martinot A; Stahl JP; Lery T; Le Danvic M; Denis F
    Med Mal Infect; 2013 Feb; 43(2):49-51. PubMed ID: 23540397
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
    Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papillomavirus vaccination in France according to 2008 to 2012 Vaccinoscopie(®) data.
    Denis F; Cohen R; Stahl JP; Martinot A; Dury V; Le Danvic M; Gaudelus J
    Med Mal Infect; 2014 Jan; 44(1):18-24. PubMed ID: 24315427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine-preventable severe morbidity and mortality caused by meningococcus and pneumococcus: A population-based study in France.
    Lorton F; Chalumeau M; Assathiany R; Martinot A; Bucchia M; Roué JM; Bourgoin P; Chantreuil J; Boussicault G; Gaillot T; Saulnier JP; Caillon J; Levy C; Cohen R; Gras-Le Guen C; Launay E
    Paediatr Perinat Epidemiol; 2018 Sep; 32(5):442-447. PubMed ID: 30170336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Northland emergency meningococcal C vaccination programme.
    Mills C; Penney L
    N Z Med J; 2013 Apr; 126(1373):30-9. PubMed ID: 23797074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution between 2008 and 2018 of mothers' perception regarding vaccination and infant vaccine coverage in France.
    Martinot A; Leboucher B; Cohen R; Stahl JP; Subtil D; Pujol P; Lepetit H; Longfier L; Gaudelus J
    Infect Dis Now; 2021 Mar; 51(2):153-158. PubMed ID: 33059002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Seroprevalence of bactericidal anti-meningococcal antibodies in Cantabria 10 months following a vaccination campaign].
    González de Aledo Linos A; García Merino J
    Rev Esp Salud Publica; 1998; 72(4):365-74. PubMed ID: 9810841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vaccination rate of premature infants at 6 and 24 months of age: a pilot study].
    Pinquier D; Adde-Michela C; Ploin D; Levêque C; Marret S;
    Arch Pediatr; 2009 Dec; 16(12):1533-9. PubMed ID: 19854629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium.
    Theeten H; Vandermeulen C; Roelants M; Hoppenbrouwers K; Depoorter AM; Van Damme P
    Acta Paediatr; 2009 Aug; 98(8):1307-12. PubMed ID: 19432835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
    De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G
    Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.